The Food and Drug Administration removed Dr. Tracy Beth Hoeg from leading the agency’s drug center program, according to an email to agency staff obtained by The Associated Press. Hoeg said on social media that she was fired, while FDA staff were told Dr. Mike Davis will replace her in an acting capacity. The leadership churn compounds an already unsettled period at the regulator. FDA Commissioner Marty Makary resigned earlier in the week, and Dr. Vinay Prasad stepped down last month amid intense external pressure from drugmakers, patients, and investors. FDA also announced that Karim Mikhail would lead the acting vaccines center. For higher education research communities—particularly those relying on stable regulatory interpretation—frequent changes at the FDA’s top-center leadership can complicate forecasting for clinical trials, safety monitoring priorities, and the policy environment surrounding widely used therapies.